Novartis AG
SGLT1/2 inhibitor LIK066 for treating obesity
Last updated:
Abstract:
The present invention is drawn to methods for effecting weight loss, e.g. in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
Status:
Grant
Type:
Utility
Filling date:
2 Mar 2018
Issue date:
23 Mar 2021